MD4291C1 - Медицинский препарат для лечения отитов - Google Patents
Медицинский препарат для лечения отитов Download PDFInfo
- Publication number
- MD4291C1 MD4291C1 MDA20130100A MD20130100A MD4291C1 MD 4291 C1 MD4291 C1 MD 4291C1 MD A20130100 A MDA20130100 A MD A20130100A MD 20130100 A MD20130100 A MD 20130100A MD 4291 C1 MD4291 C1 MD 4291C1
- Authority
- MD
- Moldova
- Prior art keywords
- otitis
- treatment
- preparation
- medicinal preparation
- medicinal
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 208000005141 Otitis Diseases 0.000 title claims abstract description 8
- 208000019258 ear infection Diseases 0.000 title claims abstract description 8
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 7
- 229960003088 loratadine Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 claims description 3
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 240000007926 Ocimum gratissimum Species 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 14
- 229940018006 basil oil Drugs 0.000 description 8
- 239000010619 basil oil Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 229960003405 ciprofloxacin Drugs 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 239000003221 ear drop Substances 0.000 description 4
- 229940047652 ear drops Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003454 tympanic membrane Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002322 anti-exudative effect Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000000613 ear canal Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002578 otoscopy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001529734 Ocimum Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к медицине, в частности к оториноларингологии, а именно к медицинскому препарату для лечения отитов.Согласно изобретению, заявленный медицинский препарат содержит для 50 мл:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130100A MD4291C1 (ru) | 2013-12-27 | 2013-12-27 | Медицинский препарат для лечения отитов |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130100A MD4291C1 (ru) | 2013-12-27 | 2013-12-27 | Медицинский препарат для лечения отитов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4291B1 MD4291B1 (ru) | 2014-07-31 |
| MD4291C1 true MD4291C1 (ru) | 2015-02-28 |
Family
ID=51228508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20130100A MD4291C1 (ru) | 2013-12-27 | 2013-12-27 | Медицинский препарат для лечения отитов |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4291C1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3369422A4 (en) * | 2015-10-29 | 2018-12-05 | Teika Pharmaceutical Co., Ltd. | External preparation |
Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382892A (en) * | 1980-09-02 | 1983-05-10 | Daiichi Seiyaku Co., Ltd. | Benzoxazine derivatives |
| US4472405A (en) * | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives |
| US4704459A (en) * | 1985-01-23 | 1987-11-03 | Toyama Chemical Co., Ltd. | Process for producing 1-substituted aryl-1,4-dihydro-4-oxonaphthyridine derivatives, and processes for producing the intermediates |
| US4730000A (en) * | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| US4861779A (en) * | 1985-09-18 | 1989-08-29 | Pfizer Inc. | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| SU1560199A1 (ru) * | 1988-01-18 | 1990-04-30 | Московский научно-исследовательский институт уха, горла и носа | Способ лечени хронических воспалительных процессов среднего уха и придаточных пазух носа |
| SU1811833A1 (ru) * | 1989-06-09 | 1993-04-30 | Vladimir I Ivanov | Способ введения лекарственных средств в ухо 2 |
| RU2040235C1 (ru) * | 1992-08-31 | 1995-07-25 | Владимир Германович Поздеев | Способ лечения острого и хронического среднего отита |
| RU2085164C1 (ru) * | 1995-10-25 | 1997-07-27 | Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи | Способ хирургического лечения хронического среднего отита |
| RU2103969C1 (ru) * | 1995-08-09 | 1998-02-10 | Юрий Петрович Ульянов | Способ лечения экзематозных отитов |
| RU96109326A (ru) * | 1993-10-21 | 1998-10-27 | Рон-Пуленк Роре С.А. | Способ получения композиций, содержащих хинолоны для орального введения |
| BG102370U (en) * | 1998-04-03 | 1999-10-29 | Khristov, Nikolaj A. | Composition make-up for making ear plugs |
| RU2160102C2 (ru) * | 1993-07-27 | 2000-12-10 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Применение бензидамина для лечения патологических состояний, вызванных фно |
| RU2163794C1 (ru) * | 2000-06-28 | 2001-03-10 | Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи | Способ лечения хронического среднего отита |
| FR2790200B3 (fr) * | 1999-02-26 | 2001-06-01 | Sanofi Sa | Formulation stable contenant de la fumagilline |
| EP0733357B1 (en) * | 1995-03-22 | 2002-07-03 | Dompé S.P.A. | Pharmaceutical formulations in form of thixotropic gel |
| RU2201736C1 (ru) * | 2001-12-24 | 2003-04-10 | Закрытое акционерное общество "Брынцалов-А" | Ушные капли бротинум |
| WO2004050021A2 (en) * | 2002-11-27 | 2004-06-17 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| MD2875G2 (ru) * | 2004-05-04 | 2006-05-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Лекарственное средство для лечения заболеваний полости носа |
| EP1228784B1 (en) * | 2001-02-06 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Preparation for veterinary use for prevention of otitis |
| MD3619G2 (ru) * | 2007-11-06 | 2009-01-31 | Рафаэль Баркан | Назальное лекарственное средство обладающее сосудосуживающим и противоотечным действием |
| RU2431486C2 (ru) * | 2004-12-09 | 2011-10-20 | Байер Энимэл Хельс ГмбХ | Лекарственное средство для гигиеничного применения на ушах |
-
2013
- 2013-12-27 MD MDA20130100A patent/MD4291C1/ru not_active IP Right Cessation
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382892A (en) * | 1980-09-02 | 1983-05-10 | Daiichi Seiyaku Co., Ltd. | Benzoxazine derivatives |
| US4472405A (en) * | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives |
| US4730000A (en) * | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| US4704459A (en) * | 1985-01-23 | 1987-11-03 | Toyama Chemical Co., Ltd. | Process for producing 1-substituted aryl-1,4-dihydro-4-oxonaphthyridine derivatives, and processes for producing the intermediates |
| US4861779A (en) * | 1985-09-18 | 1989-08-29 | Pfizer Inc. | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| SU1560199A1 (ru) * | 1988-01-18 | 1990-04-30 | Московский научно-исследовательский институт уха, горла и носа | Способ лечени хронических воспалительных процессов среднего уха и придаточных пазух носа |
| SU1811833A1 (ru) * | 1989-06-09 | 1993-04-30 | Vladimir I Ivanov | Способ введения лекарственных средств в ухо 2 |
| RU2040235C1 (ru) * | 1992-08-31 | 1995-07-25 | Владимир Германович Поздеев | Способ лечения острого и хронического среднего отита |
| RU2160102C2 (ru) * | 1993-07-27 | 2000-12-10 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Применение бензидамина для лечения патологических состояний, вызванных фно |
| RU96109326A (ru) * | 1993-10-21 | 1998-10-27 | Рон-Пуленк Роре С.А. | Способ получения композиций, содержащих хинолоны для орального введения |
| EP0733357B1 (en) * | 1995-03-22 | 2002-07-03 | Dompé S.P.A. | Pharmaceutical formulations in form of thixotropic gel |
| RU2103969C1 (ru) * | 1995-08-09 | 1998-02-10 | Юрий Петрович Ульянов | Способ лечения экзематозных отитов |
| RU2085164C1 (ru) * | 1995-10-25 | 1997-07-27 | Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи | Способ хирургического лечения хронического среднего отита |
| BG102370U (en) * | 1998-04-03 | 1999-10-29 | Khristov, Nikolaj A. | Composition make-up for making ear plugs |
| FR2790200B3 (fr) * | 1999-02-26 | 2001-06-01 | Sanofi Sa | Formulation stable contenant de la fumagilline |
| RU2163794C1 (ru) * | 2000-06-28 | 2001-03-10 | Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи | Способ лечения хронического среднего отита |
| EP1228784B1 (en) * | 2001-02-06 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Preparation for veterinary use for prevention of otitis |
| RU2201736C1 (ru) * | 2001-12-24 | 2003-04-10 | Закрытое акционерное общество "Брынцалов-А" | Ушные капли бротинум |
| WO2004050021A2 (en) * | 2002-11-27 | 2004-06-17 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| MD2875G2 (ru) * | 2004-05-04 | 2006-05-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Лекарственное средство для лечения заболеваний полости носа |
| RU2431486C2 (ru) * | 2004-12-09 | 2011-10-20 | Байер Энимэл Хельс ГмбХ | Лекарственное средство для гигиеничного применения на ушах |
| MD3619G2 (ru) * | 2007-11-06 | 2009-01-31 | Рафаэль Баркан | Назальное лекарственное средство обладающее сосудосуживающим и противоотечным действием |
Non-Patent Citations (4)
| Title |
|---|
| Grumezescu Alexandru Mihai, Chifiriuc Carmen Mariana, Marinaş Ioana, Saviuc Crina, Mihaescu Dan, Lazer Veronica. Ocium Basilicum and Menta Piperita essential oils influence the antimicrobial susceptibility of staphyloccus aureus strains. Letters in Applied NanoBioScience, vol. I, 2012.03.06 (regăsit în Internet la 203.08.13 <URL:http://nanobioletters.com/wp-content/uploads/downloads/2012/08/3.-Grumezescu-LIANBS.pdf>) * |
| Matcovschi C., Procopişin V., Parii B. Ghid farmacoterapeutic. Chişinău, 2006, p. 968 * |
| Stroescu Valentin. Bazele farmacologice ale practicii medicale. Editura medicala, Bucuresti, 1999, p. 357-358 * |
| Дмитриевская Лилия. Обманывая возраст. Практика омоложения. Эксклюзивные методики аромакосметологии и терапии. Базилик (Ocimum basilicum). 2009, p. 61 (regăsit în Internet la 2013.08.13 <URL:http://library.aromazona.ru/dmitrievskaya/page/60.html>) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3369422A4 (en) * | 2015-10-29 | 2018-12-05 | Teika Pharmaceutical Co., Ltd. | External preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4291B1 (ru) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12257263B2 (en) | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting | |
| CA2862406C (en) | Otic formulations, methods and devices | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| EP3030084A2 (en) | Organophosphates for treating afflictions of the skin | |
| Goossens et al. | Contact allergy to topical drugs | |
| US11878008B2 (en) | Composition for preventing or treating atopic dermatitis | |
| Zanoveli et al. | Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine | |
| AU2026201359A1 (en) | Otic formulations, methods and devices | |
| CN104127500A (zh) | 预防感冒的芳香精油、芳香鼻贴及其制备方法 | |
| CN103877005A (zh) | 一种复方奥氮平皮下埋植缓释剂 | |
| JP7191022B2 (ja) | アルカフタジン又はその塩を含有する水性医薬組成物 | |
| US20100190860A1 (en) | Methods for selectively enhancing antinociceptive potency of local anesthetics | |
| US10438128B2 (en) | Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally | |
| CA3153832C (en) | Otic formulations, methods and devices | |
| Chouati | Emulgel technological properties for the dermatitis treatment investigation | |
| CN101259093B (zh) | 鼻腔清洁护理溶液 | |
| Comer et al. | Cigarette smoke, airway epithelial cells and host defence | |
| RU2628811C1 (ru) | Применение производного лидокаина, обладающего местноанестезирующей активностью, для терминальной анестезии | |
| Shete et al. | Evaluation of the efficacy of ozone gas therapy against conventional topical corticosteroids for the management of oral reticular lichen planus | |
| CN102921051A (zh) | 除螨贴的配方与制备 | |
| OTC et al. | Eucerin Protective Lotion (OTC) Lotn: 4 oz (alcohol) | |
| UA129751U (uk) | Фармацевтична композиція у формі назального гелю з антимікробною та противірусною (відносно аденовірусу) дією | |
| Pettersson | tinidazole gives excellent results (3, 5, 8). This" flash therapy | |
| UA69564U (ru) | Композиция назальная в виде раствора для капельного или аэрозольного введения в носовые ходы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |